Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Boceprevir Triple Therapy in HCV-1 Patients with Insulin Resistance
NCT01770223Phase 4Withdrawn
- Sponsor
- Merck & Co.
- Start
- Jan 2014
- Primary completion
- Dec 2015
- Modality
- Orthosteric Ligands
01
Overview
A Phase 4 trial of boceprevir in hepatitis C (HCV), sponsored by Merck & Co.. Planned start Jan 2014; status: withdrawn.
02
Drugs
boceprevir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT01770223.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01770223.